



26 February 2014

Companies Announcement Office
ASX Limited
Exchange Centre
Level 4, 20 Bridge Street
Sydney, NSW 2000

Diagnostic Array Systems Pty Ltd – Patent Update For BacTrak Diagnostic Test

Please find attached an operational update from BPH Energy Ltd (**ASX: BPH**) investee company Diagnostic Array Systems Pty Ltd.

Yours sincerely,

Deborah Ambrosini
Director and Company Secretary



26 February 2014

BPH Energy Limited
14 View Street
North Perth, WA 6006

Patent Update For BacTrak Diagnostic Test

Diagnostic Array Systems Pty Ltd (DAS) is pleased to provide the following update of its patent portfolio.

The patent application entitled 'Method for the Detection and/or identification of a micro-organism' has been granted within both, Australia and the United States. The patent, which underpins the BacTrak system, covers a method for simultaneous detection or identification of multiple micro-organisms from a single patient sample. This is DAS' second and third granted patents and both of these patents have an exclusivity period until July 2026.

The BacTrak system is an *in-vitro* diagnostic tool that enables simultaneous identification of multiple bacterial pathogens that cause respiratory illness, including Pneumonia, Tuberculosis (TB) and Legionnaires' disease. The BacTrak method uses specific DNA sequences for detecting and differentiating bacteria. DNA extracted from a sample is amplified and hybridized to bacteria specific probes, the hybridized products are then analysed for identification. This sensitive and highly specific method allows for the rapid identification of bacterial pathogens that cause respiratory illness.

Efficient treatment for bacterial respiratory infections hinges on the accurate and timely diagnosis of the bacterial species. Current diagnostic methods, however, are slow and can impact on patient care. The BacTrak system has important implications for the clinical management of infectious disease by rapidly identifying the specific bacteria responsible for the disease and suggesting the most effective treatment in a timely fashion. Utilisation of the novel test is intended to provide more information more quickly than alternative methods. It has the potential to accelerate therapeutic treatment, lead to a reduction in hospitalisation and help reduce the overuse of antibiotics.

Yours Sincerely,

A handwritten signature in black ink, appearing to read "D. Breeze", with a stylized flourish at the end.

David Breeze
Director

Diagnostic Array Systems Pty Ltd

ACN 103 314 049

PO box 317, North Perth, WA, 6906

14 View Street, North Perth, Western Australia

T: + 61 8 9328 8366 F: +61 8 9328 8733

admin@bphenergy.com.au www.bphenergy.com.au